Association of Antihypertensive Drug Target Genes With Psychiatric Disorders: A Mendelian Randomization Study

Key Points

Question  Can the potential effects of different antihypertensive drug classes on psychiatric disorders be estimated using genetic data?

Findings  This genetic association study used a 2-sample mendelian randomization analysis and found that lower genetically estimated angiotensin-converting enzyme (ACE) messenger RNA and protein expression, as proxies for ACE inhibitor treatment, were associated with increased risk of schizophrenia.

Meaning  These findings warrant greater pharmacovigilance and further investigation through pharmacoepidemiology studies into the effect of ACE inhibitors, particularly those that are centrally acting, on psychiatric symptoms in patients with schizophrenia, as well as with incidence of late-onset schizophrenia.

Importance  Observational studies have reported associations between antihypertensive medication and psychiatric disorders, although the reported direction of association appears to be dependent on drug class.

Objective  To estimate the potential effect of different antihypertensive drug classes on schizophrenia, bipolar disorder, and major depressive disorder.

Design, Setting, and Participants  This 2-sample mendelian randomization study assessed the association between a single-nucleotide variant (SNV) and drug target gene expression derived from existing expression quantitative trait loci (eQTL) data in blood (sample 1) and the SNV-disease association from published case-control genome-wide association studies (sample 2). Significant associations were corroborated using published brain eQTL and protein QTL data. Participants included 40 675 patients with schizophrenia and 64 643 controls, 20 352 patients with bipolar disorder and 31 358 controls, and 135 458 patients with major depressive disorder and 344 901 controls. Blood eQTL levels were measured in 31 684 individuals from 37 cohorts (eQTLGen consortium); prefrontal cortex eQTLs were measured from the PsychENCODE resource in 1387 individuals; and protein QTLs were measured in cerebral spinal fluid from 544 individuals and plasma from 818 individuals. Data were collected from October 4, 2019, to June 1, 2020, and analyzed from October 14, 2019, to June 6, 2020.

Exposures  Expression levels of antihypertensive drug target genes as proxies for drug exposure, and genetic variants robustly associated with the expression of these genes as mendelian randomization instruments.

Main Outcomes and Measures  Risk for schizophrenia, bipolar disorder, and major depressive disorder.

Results  A 1-SD lower expression of the angiotensin-converting enzyme (ACE) gene in blood was associated with lower systolic blood pressure of 4.0 (95% CI, 2.7-5.3) mm Hg, but increased risk of schizophrenia (odds ratio [OR], 1.75; 95% CI, 1.28-2.38; P = 3.95 × 10⁻⁴). A concordant direction of association was also observed between ACE expression in prefrontal cortex (OR, 1.33; 95% CI, 1.13-1.56) and ACE protein levels in cerebral spinal fluid (OR per 1-SD decrease, 1.12; 95% CI, 1.05-1.19) and plasma (OR per 1-SD decrease, 1.04; 95% CI, 1.01-1.07). We found no evidence for an association between genetically estimated SBP and schizophrenia risk.

Conclusions and Relevance  Findings suggest an adverse association of lower ACE messenger RNA and protein levels with schizophrenia risk. These findings warrant greater pharmacovigilance and further investigation into the effect of ACE inhibitors, particularly those that are centrally acting, on psychiatric symptoms in patients with schizophrenia, as well as the role of ACE inhibitor use in late-onset schizophrenia.

A higher cardiovascular morbidity and mortality in individuals with psychiatric disorders has been partly attributed to both a higher incidence of risk factors for cardiovascular disease and less effective clinical management.¹ Presence of risk factors for cardiovascular disease may be due to unfavorable effects of antipsychotic medication, adverse dietary habits, lack of exercise, and increased substance use. However, evidence of shared pathophysiological mechanisms also exists. A genome-wide association study (GWAS) of bipolar disorder, for example, identified genetic risk variants within the CACNA1C gene, whose encoded protein is the target of antihypertensive calcium channel blockers.² The directionality of effect, if any, of this class of drugs on bipolar disorder remains unclear.^3,4 Observational studies have reported associations between antihypertensive medication and psychiatric disorders, although the reported direction of association appears to depend on the drug class,^5,6 suggesting that any effect could be independent of their blood pressure–lowering effect. Given the high prevalence of hypertension in patients with psychiatric disorders, understanding whether these medications may cause, exacerbate, or relieve neuropsychiatric symptoms will enable clinicians to make better-informed prescription decisions in comorbid individuals.

The criterion standard approach for determining a causal effect of drug treatment would be randomized clinical trials (RCTs). However, RCTs are expensive and may not always be feasible, which may explain a current lack of large, high-quality RCTs investigating the effects of antihypertensives on psychiatric disorders. Mendelian randomization (MR) is a statistical genetics approach that uses genetic variants that are robustly associated with an exposure as potentially unconfounded instruments to infer whether an observed association between the exposure and outcome is causal or not. Genetic variants that are associated with drug target messenger RNA expression or protein levels, also referred to as expression or protein quantitative trait loci (eQTLs or pQTLs, respectively), can be used as MR instruments for drug exposure (Figure 1). Given that all assumptions are satisfied (eMethods in Supplement 1), MR analysis can be used to overcome 2 major limitations of observational studies: unmeasured confounding and the ability to infer cause or consequence.⁷ Recent examples of MR analyses with psychiatric disorders include investigating the association of vitamin D, inflammatory biomarkers, and metabolic traits with schizophrenia risk.^8,9

In this study, we aimed to identify potential association of antihypertensive treatment with psychiatric disorders using a 2-sample MR analysis. We used publicly available eQTL data to identify suitable genetic instruments for blood pressure–lowering drug target gene expression (as a proxy for drug exposure). We combined these data with summary data from the most recent and largest GWAS of psychiatric disorders in a 2-sample MR analysis.

This genetic association study used only published summary data from studies involving human participants, with written informed consent and approval by their respective institutional ethics review committees. This study is covered under the University of Queensland Human Research Ethics Committee approval. We followed the Strengthening the Reporting of Observational Studies in Epidemiology–Mendelian Randomization (STROBE-MR) reporting guidelines. The full period of data collection was October 4, 2019, to June 1, 2020.

Drug target data were collected from October 4 to 11, 2019. Using the World Health Organization Collaborating Centre for Drug Statistics Methodology, we identified different classes of blood pressure–lowering drugs, as classified by the Anatomical Therapeutic Chemical classification system, and obtained a list of active ingredients within each drug class. Genes whose protein products are targeted by any one of these active ingredients were identified using the DrugBank¹⁰ (https://go.drugbank.com/) and ChEMBL¹¹ (https://www.ebi.ac.uk/chembl/) databases. If a gene was named as a target in only 1 database, we looked at the referenced publications to determine whether experimental evidence was sufficient for inclusion as a drug target gene.

We used publicly available data from the eQTLGen consortium (n = 31 684)¹² (eTable 1 in Supplement 2) to identify common (minor allele frequency >1%) single-nucleotide variants (SNVs) associated with the expression of antihypertensive drug target genes in blood. Only cis associations are available in the eQTLGen data (distance between SNV and gene is <1 megabase). The eQTL data are on the scale of a 1-SD change in the expression level of the gene for each additional effect allele. The SNV instrument strength was assessed using the F statistic (details provided in the eMethods in Supplement 1).

We obtained publicly available (prevalent) case-control GWAS summary data for schizophrenia (40 675 cases and 64 643 controls, approximately 95% European ancestry),¹³ bipolar disorder (20 352 cases and 31 358 controls of European ancestry),¹⁴ and major depressive disorder (135 458 cases and 344 901 controls of European ancestry)¹⁵ (eTable 2 in Supplement 2). Further details of samples and GWA analyses are provided elsewhere.^13-15

We used the summary-based MR (SMR) method, version 1.02,¹⁶ to perform 2-sample MR analysis (eMethods in Supplement 1). To show that changes in gene expression reflect a blood pressure–lowering association with drug exposure, we performed SMR analysis with blood gene expression (using the eQTLGen data) as exposure and systolic blood pressure (SBP) as the outcome, using summary data from a GWAS of SBP in 757 601 individuals of European ancestry¹⁷ (eTable 2 and eFigure 3 in Supplement 2). Genes whose expression in blood was not associated with SBP with at least nominal significance (ie, P ≥ .05) were excluded from further analysis. The effect size estimate from SMR for the association between gene expression and SBP represents the change (in millimeters of mercury) in SBP per 1-SD increase in gene expression.

We ran an SMR analysis to estimate the association of a 1-SD change in drug target blood gene expression levels (using eQTLGen data) with outcomes of interest (using GWAS summary data for schizophrenia, bipolar disorder, and major depressive disorder). Main results are presented as the odds ratio (OR) for disease per 1-SD change in gene expression, where the direction of gene expression change is harmonized to reflect an SBP-lowering association. The effect size estimates in the main results therefore suggest the potential direction of association of antihypertensive drug exposure with risk of psychiatric disorders. Bonferroni correction for multiple testing was used to identify significant associations.

Data were analyzed from October 14, 2019, to June 6, 2020. For significant MR associations, additional sensitivity analyses were performed, including assessing horizontal pleiotropy, colocalization analysis, simulation of the effect of selection bias, and ancestry-specific analyses. Where available, analyses using additional data sets were used to corroborate the main findings (eMethods in Supplement 1).

For significant MR associations, to determine whether the association between drug target gene expression and disease risk is likely to be mediated via changes in blood pressure or whether the association may be independent of blood pressure, we estimated the effect size for the association between genetically estimated SBP and the relevant psychiatric outcome using the generalized summary data–based MR method,¹⁸ an extension of SMR that uses multiple genetic variants associated with the risk factor to test for potential causality. We used summary data from the largest available GWAS on SBP in European individuals¹⁷ (eTable 2 in Supplement 2). Analysis was performed using generalized summary data–based MR implemented in GCTA (Genome-wide Complex Trait Analysis), version 1.91.7beta1. The default heterogeneity in dependent instrument (HEIDI) P < .01 was used to exclude pleiotropic SNVs. As sensitivity analyses, we also performed 2-sample MR analysis using other methods implemented in the TwoSampleMR, version 0.5.5, R package (R Project for Statistical Computing). Although all methods use the same underlying MR framework, the different methods have different specific assumptions that can lead to biased estimates in different situations. Agreement across methods provides more confidence that results may be robust. Analysis scripts are found at https://github.com/CNSGenomics/Antihypertensive-med.

We identified a total of 110 genes whose encoded protein activity has been experimentally shown to be modified by 1 or more blood pressure–lowering drugs (eTable 3 in Supplement 2). Although 109 of 110 were reported by eQTLGen to be expressed in blood, 48 of the protein-encoding genes were absent in the meta-analyzed eQTLGen summary data, because they showed no variation in expression across samples and were filtered out during meta-analysis. We were therefore only able to query the eQTL data for 61 of the 110 drug target genes. For all 61 genes, the most significant cis-eQTL SNVs selected as genetic instruments had F statistics of greater than 10 (eTable 4 in Supplement 2). Of the 61 genes, 22 had gene expression levels in blood that were associated with SBP at nominal significance (SMR P < .05) (eTable 4 in Supplement 2), and these were taken forward to the main analysis.

Using a significance threshold of P < 7.58 × 10⁻⁴ (Bonferroni correction for association testing of 22 genes with 3 disease phenotypes) and a HEIDI P ≥ .01 to rule out association due to linkage, we found that a 1-SD decrease in blood ACE expression (target for ACE inhibitors) was associated with a decrease in SBP of 4.0 (95% CI, 2.7-5.3) mm Hg and a higher risk of schizophrenia (OR, 1.75; 95% CI, 1.28-2.38; P = 3.95 × 10⁻⁴) (Figure 2A). Colocalization analysis gave a posterior probability of 85% for a common variant for ACE (OMIM 106180) expression and schizophrenia risk. Although expression of CYP17A1 (OMIM 609300; targeted by spironolactone, a potassium-sparing diuretic) and NISCH (OMIM 615507; targeted by moxonidine, a new-generation α-2/imidazoline receptor agonist) were associated with schizophrenia and bipolar disorder, the significant HEIDI P values suggest these associations were likely due to linkage. This possibility is corroborated by the low to moderate posterior probabilities for a common variant for these associations (<0.1% for CYP17A1 expression and schizophrenia risk, 53% for CYP17A1 expression and bipolar disorder risk, <0.1% for NISCH expression and schizophrenia risk, 36% for NISCH expression and bipolar disorder risk). These associations were therefore not taken forward for further analyses. The SMR results from the analysis between expression of the 22 drug target genes in blood with the 3 psychiatric disorders are provided in eTables 5 to 7 in Supplement 2. We observed concordant direction of association between ACE expression and schizophrenia risk using schizophrenia GWAS data from European ancestry–only and East Asian ancestry–only samples (eTable 8 in Supplement 2).

The eQTL SNP instrument for expression of ACE in brain prefrontal cortex (rs6504163) was in high linkage disequilibrium with the blood eQTL (r² = 0.93 in individuals of European ancestry). As observed in blood samples, lower ACE expression in the prefrontal cortex was associated with higher risk of schizophrenia (OR, 1.33; 95% CI, 1.13-1.56; P = 5.69 × 10⁻⁴) (Figure 3). We observed concordant direction of association using schizophrenia GWAS data from individuals of European and East Asian ancestry (eTable 8 in Supplement 2). Extending analysis to other brain regions, significant associations between ACE expression with schizophrenia risk were observed for cortex regions, cerebellum, and cerebral hemisphere after multiple testing correction (P < 3.57 × 10⁻³) (Figure 3).

The eQTL SNV instrument for ACE expression in blood (rs4277405) was also associated with the expression of 10 adjacent genes at P < .05, including 5 genes at P < 1×10⁻⁵ (FTSJ3 [OMIM 618411], TANC2 [OMIM 615047], SMARDC2 [OMIM 601736], ICAM2 [OMIM 146630], and STRADA [OMIM 608626]) in blood samples (eTable 9 in Supplement 2). However, SMR and colocalization analyses did not provide any evidence of an association between expression of these adjacent genes with schizophrenia (eTable 10 in Supplement 2) and, therefore, no evidence for horizontal pleiotropy.

We used rs4343, a proxy for the ACE indel that has previously been associated with ACE activity¹⁹ and is not highly correlated with the ACE blood eQTL rs4277405 (r² = 0.35 in individuals of European ancestry), as an instrument. We observed a concordant direction of association of a 1-SD decrease in ACE gene expression in blood with lower SBP (β = −2.40 mm Hg; SE, 0.76 mm Hg; P = 1.75 × 10⁻³), and higher risk of schizophrenia (OR, 1.81; 95% CI, 1.36-2.26; P = 9.40 × 10⁻³) (eTable 11 in Supplement 2).

Because AGT (OMIIM 106150), AGTR1 (OMIM 106165), and REN (OMIM 179820) were absent in the blood eQTL summary data set, we queried brain eQTL data. The eQTL SNV instruments for expression of AGT, AGTR1, and REN in brain tissue all had F statistics of greater than 10. We found no evidence of an association between expression of these 3 renin-angiotensin system (RAS) pathway genes in brain tissue and schizophrenia risk (eTable 12 in Supplement 2).

Using summary data from GWAS of plasma and cerebrospinal fluid ACE levels, a 1-SD decrease in ACE protein levels in plasma (OR, 1.04; 95% CI, 1.01-1.07; P = 4.41 × 10⁻³) and cerebrospinal fluid (OR, 1.12; 95% CI, 1.05-1.19; P = 9.44 × 10⁻⁴) were associated with increased schizophrenia risk. We observed concordant effect sizes using a multi-SNV MR approach that included 1 cis and 1 trans-SNV associated with plasma ACE levels (eFigure 1 in Supplement 1). Reverse MR analysis found no association of schizophrenia case-control status with ACE protein levels (eTable 13 in Supplement 2). The results of these sensitivity analyses of ACE and schizophrenia risk are summarized in eFigure 2 in Supplement 1.

Using 727 SNVs that were independently associated at genome-wide significance (GWAS association P < 5 × 10⁻⁸) with SBP as MR instruments (after HEIDI outlier filtering to remove pleiotropic SNVs), we found no evidence to support an association between genetically estimated SBP and schizophrenia risk (OR per 1–mm Hg increase, 1.00; 95% CI, 0.99-1.00; P = .14) (eFigure 3 in Supplement 1). Results were consistent without HEIDI outlier filtering and using other MR methods (eTable 14 in Supplement 2).

We used QTL and GWAS summary data in a 2-sample MR analysis to infer potential effects of antihypertensive medication on psychiatric disorders. Lower expression of the ACE gene, a target for ACE inhibitors, was associated with decreased SBP but increased risk of schizophrenia. A summary of the study design and results is shown in Figure 4. We found no evidence for an association between genetically estimated SBP and schizophrenia risk. This suggests that even small potential effects of blood pressure on schizophrenia are unlikely and implies that any association of ACE with schizophrenia is likely to be independent of its association with blood pressure.

ACE is a component of the RAS that regulates blood pressure. In addition to the circulating RAS, nearly all organs of the body have their own local paracrinelike RAS, with organ-specific actions.²⁰ Although we were unable to test the association between expression of other RAS components in blood, we found little evidence for an association between expression in brain tissues of other RAS pathway genes, namely AGT, AGTR1, and REN, with schizophrenia risk. Larger brain eQTL data sets would be needed to rule out small but clinically relevant effects of these genes. ACE consists of 2 catalytic domains, the C-domain and N-domain. The N-domain has been shown to bind multiple substrates with varying affinities.²¹ The location of ACE on the cellular membrane of neurons and its ability to cleave several neuropeptides suggests a role for ACE in central nervous system functions. ACE has also been shown to play a role in innate and adaptive immunity,²² which is also implicated in the pathogenesis of schizophrenia.²³

An MR analysis of antihypertensive drug exposure and risk of psychiatric disorders has not been previously conducted. Observational studies have reported contradictory associations. Boal et al⁵ found that calcium channel antagonists and β-blockers were associated with increased risk of mood disorder admissions, whereas users of drugs targeting the RAS pathway had the lowest risk. Hayes et al⁶ found reduced rates of psychiatric hospitalization and self-harm in patients with bipolar disorder and schizophrenia who were treated with calcium channel antagonists, but the investigators did not look at other antihypertensive drug classes. A systematic review of 23 studies investigating verapamil hydrochloride, a calcium channel blocker, in acute mania, found no evidence of an effect.³

Previous genetic studies^24,25 have identified an association between the ACE insertion/deletion and schizophrenia; however, the findings have been contradictory. Similarly, paradoxical findings can be found for ACE activity and protein levels when comparing patients with schizophrenia with controls.^26,27 The Schizophrenia Working Group of the Psychiatric Genetics Consortium²⁸ recently published a preprint of the latest schizophrenia GWAS, consisting of 39 369 cases and 236 642 controls. They report variants within the ACE gene reaching genome-wide significance for the first time and SMR analysis showing an association of decreased ACE expression in blood with increased risk of schizophrenia, corroborating our findings.

This study has some particular strengths. Human genetics is an increasingly crucial source of evidence guiding the selection of new targets for drug discovery as well as evaluating drug safety.^29,30 Loss-of-function mutations in the drug target genes would make for ideal MR instruments. However, given such variants are very rare, an MR study using loss-of-function variants would not currently be feasible.³¹ Alternatively, eQTL variants can be used as MR instruments. Two-sample MR analysis allows us to use the largest available GWAS and eQTL data sets to investigate causality by overcoming some of the caveats of observational studies and RCTs, such as sample size, confounding bias, and feasibility, while using cis-SNVs to instrument messenger RNA or protein expression minimizes the potential for horizontal pleiotropy, which would violate an assumption of MR.

Several sensitivity analyses suggest a robust association between ACE expression and schizophrenia. Figure 5 summarizes the possible scenarios that may lead to the observed association between ACE expression and schizophrenia risk and the analyses performed to assess these scenarios.

In terms of limitations, reduced life expectancy in individuals with schizophrenia may be accelerated by the presence of cardiovascular disease. This could lead to survival bias in case-control GWAS data, because studies included prevalent cases. However, our simulations show that the observed association is unlikely to be driven by selection bias (eTables 15 and 16 in Supplement 1).

This study assumes that changes in gene expression may reflect changes in protein levels and/or activity, which may not always be the case. Therefore, lack of association in our analysis does not necessarily mean lack of biological effect of drug treatment, but rather lack of evidence that change in drug target gene expression in the tested tissues is not associated with outcome, which could also reflect power to detect an outcome (for power calculations, see eTables 18-20 in Supplement 1). The effect sizes estimated from MR analysis may not reflect the true effect of drug exposure. Variables such as drug dose, duration of exposure, interindividual variation in drug metabolism, ability to reach the tissue of relevance (eg, cross the blood-brain barrier), and drug-binding affinity all play a role in modifying drug efficacy and toxicity, making it difficult to extrapolate the actual effect of drug exposure from genetic analyses.

The power to conduct tissue-specific analysis is currently restricted by sample size of available eQTL data sets. Although relatively high correlation has been observed between blood and brain eQTLs,³² any extrapolation will be restricted to genes that are expressed and have eQTLs in both. Given the small brain eQTL sample sizes and varying instrument strength in the different brain regions (eTable 17 in Supplement 1), smaller but clinically relevant effects of ACE expression in other brain regions cannot be ruled out.

Genetic variants may reflect the effect of lifelong exposure on an outcome. Although results from these analyses cannot be directly translated into effects of short-term drug treatment on disease risk, they may prove useful in estimating effects of long-term exposure beyond what is feasible in RCTs.

In this study, we found an adverse association of lower ACE messenger RNA and protein levels with schizophrenia risk, with sensitivity analyses suggesting that any association of ACE with schizophrenia risk is likely to be independent of its association with blood pressure. Although approximately 20% of individuals with schizophrenia are reported to have late-onset disease (>40 years of age),³³ for most patients, onset occurs in late adolescence or early adult life, ruling out ACE inhibitor treatment as a potential causal factor for most cases. However, if lower ACE levels play a causal role for schizophrenia risk, it would be reasonable to hypothesize that further lowering of ACE activity in existing patients could worsen symptoms or trigger a new episode. We cannot draw full conclusions with statistical evidence alone, and these results are not sufficient to justify changes to current prescription guidelines, especially given their known beneficial cardiovascular effects. However, given that visual hallucinations and reversible psychosis have been reported after ACE inhibitor treatment,^34-38 our findings warrant further research into the functional role of ACE in schizophrenia, as well as greater pharmacovigilance. Access to massive electronic health record databases provide the opportunity to conduct pharmacoepidemiological studies to look at the association between ACE inhibitor use and psychiatric symptoms, hospitalization, and mortality in patients with schizophrenia, or with the incidence of late-onset schizophrenia. However, the issue of sample size for the latter, given the low prevalence, and inaccurate recording of psychiatric symptoms, are important considerations for such studies in the future.

Accepted for Publication: December 23, 2020.

Published Online: March 10, 2021. doi:10.1001/jamapsychiatry.2021.0005

Corresponding Author: Sonia Shah, PhD, Institute for Molecular Biosciences, University of Queensland, 302 Carmody Rd, St Lucia, 4072 Queensland, Australia (s.shah1@uq.edu.au).

Author Contributions: Mr Chauquet and Dr Shah had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Shah.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Shah.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Chauquet, Zhu, Wray, Shah.

Obtained funding: Wray.

Administrative, technical, or material support: Zhu, Wray.

Supervision: Shah.

Conflict of Interest Disclosures: Dr O’Donovan reported receiving grants from the Medical Research Council UK and the National Institute of Mental Health during the conduct of the study and grants from Takeda Pharmaceuticals Company Limited outside the submitted work. Dr Walters reported receiving grants from Takeda Pharmaceutical Company Limited outside the submitted work. No other disclosures were reported.

Funding/Support: This study was supported by program grants 1078901 and 1113400 (Dr Wray) and a fellowship (Dr Shah) from the National Health and Medical Research Council and by project grant R01MH100141 from the National Institute for Mental Health (Dr Wray).

Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: This study has been possible thanks to publicly available genome-wide association study (GWAS) and expression quantitative trait loci (eQTL) summary statistics, including that from the Psychiatric Genetics Consortium (includes GWAS summary statistics for major depression from 23andMe, the eQTLGen Consortium, the GTEx Project, and the PsychENCODE Project data). Carlos Cruchaga, PhD, and Fabiana Geraldo Farias, PhD, Washington University in St Louis, for provided the full GWAS summary statistics for angiotensin-converting enzyme plasma and cerebrospinal fluid levels, for which they were not compensated. Data from the UK Biobank Resource under application 12505 was used.